George Martin, MD, founder and program director of the Maui Derm meeting, highlights new strategies in psoriasis treatment in the second half of his summary. Among them is an interleukin (IL)-23 inhibiting biologic drug that is administered only once or twice. IL-17 inhibitors, such as brodalumab, were significantly more effective than placebo in improving psoriatic arthritis symptoms in 168 patients after 12 weeks. Serious adverse events occurred in 3 percent of patients on brodalumab and in 2 percent on placebo. TNF-alpha inhibitors, including pegylated CZP, are approximately equally effective for psoriatic arthritis but differ in efficacy for cutaneous psoriasis. No IL-23 inhibitor, such as tildrakizumab or guselkumab, is yet approved for psoriatic arthritis, but studies are ongoing. Topical therapy remains the mainstay, especially for skin involvement of 2-5 percent of the body surface area (BSA)[1].